Literature DB >> 24523617

Early prediction of treatment response in advanced gliomas with (18)F-dopa positron-emission tomography.

Nicholas Dowson1, Paul Thomas2, Michael Fay3, Rosalind L Jeffree4, Yaniv Gal5, Pierrick Bourgeat6, Jye Smith7, Craig Winter8, Alan Coulthard9, Olivier Salvado6, Stuart Crozier5, Stephen Rose10.   

Abstract

Entities:  

Year:  2014        PMID： 24523617      PMCID： PMC3921044          DOI： 10.3747/co.21.1772

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  5 in total

1.  Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.

Authors:  Norbert Galldiks; Marion Rapp; Gabriele Stoffels; Gereon R Fink; Nadim J Shah; Heinz H Coenen; Michael Sabel; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-29       Impact factor: 9.236

2.  18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.

Authors:  Robert J Harris; Timothy F Cloughesy; Whitney B Pope; Phioanh L Nghiemphu; Albert Lai; Taryar Zaw; Johannes Czernin; Michael E Phelps; Wei Chen; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

3.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Authors:  F M Iwamoto; L E Abrey; K Beal; P H Gutin; M K Rosenblum; V E Reuter; L M DeAngelis; A B Lassman
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

4.  Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.

Authors:  Wei Chen; Sibylle Delaloye; Daniel H S Silverman; Cheri Geist; Johannes Czernin; James Sayre; Nagichettiar Satyamurthy; Whitney Pope; Albert Lai; Michael E Phelps; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

5.  Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.

Authors:  Deanna H Pafundi; Nadia N Laack; Ryan S Youland; Ian F Parney; Val J Lowe; Caterina Giannini; Brad J Kemp; Michael P Grams; Jonathan M Morris; Jason M Hoover; Leland S Hu; Jann N Sarkaria; Debra H Brinkmann
Journal:  Neuro Oncol       Date:  2013-03-03       Impact factor: 12.300
  5 in total
  2 in total

1.  18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.

Authors:  Chirag B Patel; Elisa Fazzari; Ararat Chakhoyan; Jingwen Yao; Catalina Raymond; Huytram Nguyen; Jasmine Manoukian; Nhung Nguyen; Whitney Pope; Timothy F Cloughesy; Phioanh L Nghiemphu; Johannes Czernin; Albert Lai; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2018-04-20       Impact factor: 4.130

2.  Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature.

Authors:  François Somme; Laura Bender; Izzie Jacques Namer; Georges Noël; Caroline Bund
Journal:  Cancer Imaging       Date:  2020-10-06       Impact factor: 3.909
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.